Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown inotuzumab ozogamicin B-cell adult acute lymphocytic leukemia not applicable detail...
Unknown unknown Disarib + Paclitaxel B-cell adult acute lymphocytic leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting
NCT02924402 Phase I XmAb13676 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting
NCT03441061 Phase II inotuzumab ozogamicin Study of Inotuzumab Ozogamicin in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease Recruiting
NCT03642626 Phase II Cyclophosphamide + Fludarabine + Tisagenlecleucel Cyclophosphamide + Fludarabine + KTE-C19 MT2017-45: CAR-T Cell Therapy for Heme Malignancies Recruiting
NCT03876769 Phase II Tisagenlecleucel Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA) Recruiting
NCT03913559 Phase II inotuzumab ozogamicin Cytarabine + Hydrocortisone + Methotrexate Acetaminophen + Diphenhydramine + Methylprednisolone Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia Recruiting
NCT03962465 Phase I Daunorubicin + inotuzumab ozogamicin + Pegaspargase + Prednisone + Vincristine Daunorubicin + inotuzumab ozogamicin + Prednisone + Vincristine Cytarabine Methotrexate Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001) Not yet recruiting